Is very happy to announce the outcomes of a study.

Conversely, a low PlGF level identified women at high risk for preterm delivery accurately, and 94 percent of females with an abnormal check result went on to require early delivery. Professor of Obstetric Medication at the University of Oxford and PELICAN investigator, Christopher Redman commented, ‘Pre-eclampsia is certainly notoriously unpredictable. Reliable tests which you can use in the clinical setting, when pre-eclampsia is certainly first suspected, would be a notable breakthrough in the administration of this life-threatening condition. The PELICAN data have demonstrated that PlGF testing before 35 weeks enables physicians to categorise ladies into low and risky for disease progression also to adjust clinical administration appropriately.’ Related StoriesMaintaining normal BMI after pregnancy might help prevent pelvic organ prolapseNew study discovers high prevalence of HIV among pregnant refugee women in OntarioWeb-based app assists females to maintain good health long before pregnancyPre-eclampsia is certainly a harmful condition that can develop during pregnancy and, if still left untreated, can lead to significant maternal organ harm, foetal growth restriction and, in some cases, foetal or maternal loss of life.Simonton, M.D., FACC, FSCAI, divisional vice president, Medical Affairs, and chief medical officer, Abbott Vascular. ‘We look forward to evaluating the outcomes of the trials, which we plan to submit to support regulatory approvals of the device.’ Absorb functions by opening a blocked vessel and restoring blood circulation to the heart comparable to a metallic stent; however, unlike a metallic stent, Absorb dissolves over time, possibly leaving behind a more flexible vessel because it is free from a long lasting metallic stent which cages the vessel. Absorb is referred to as a scaffold to point that it is a temporary structure, unlike a metallic stent, which really is a long term implant.